Litcius/Paper detail

Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma

Karin Hansson, Katarzyna Radke, Kristina Aaltonen, Jani Saarela, Adriana Mañas, Jonas Sjölund, Emma Smith, Kristian Pietras, Sven Påhlman, Krister Wennerberg, David Gisselsson, Daniel Bexell

2020Science Translational Medicine33 citationsDOIOpen Access PDF

Abstract

-amplified neuroblastoma PDX tumors. Furthermore, treatment of mice harboring orthotopic neuroblastoma PDX tumors resulted in increased survival. Our results suggested that KSP inhibition could be a promising treatment strategy in children with high-risk neuroblastoma.

Topics & Concepts

NeuroblastomaCancer researchProgrammed cell deathMitosisMedicineOncologyBiologyApoptosisCell biologyCell cultureGeneticsNeuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma | Litcius